DelveInsight’s ‘Celiac Disease (CD) - Epidemiology Forecast – 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Celiac Disease (CD) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Celiac Disease (CD) Understanding
Celiac Disease (CD)—also known by coeliac disease, celiac sprue, non-tropical sprue, and gluten-sensitive enteropathy—is a chronic, immune-mediated enteropathy in which dietary gluten triggers an inflammatory reaction in the small intestine of genetically predisposed individuals. Gluten is a water-insoluble protein mass that remains when the wheat dough is washed to remove starch, albumins and other water-soluble proteins. Gluten and gluten-related proteins are present in wheat, rye and barley and are used widely in food processing to give the dough the desired baking properties, add flavors and improve texture. In celiac subjects, the ingestion of gluten leads to an enteropathy with an impairment of the mucosal surface and, consequently, abnormal absorption of nutrients. CD might be considered a syndrome, because of the wide spectrum of clinical manifestations and the involvement of various human systems.
CD shows atypical features in comparison to other autoimmune disorders, including the complete recovery of the mucosal damage as well as the reversibility of its progression and chronic dynamics, with total avoidance of gluten. Alternatively, it is now established that undiagnosed CD, might have severe consequences in children as well as in adult subjects.
CD is one of the better-characterized diseases related to the immune system with all the affected patients having the following:
• a genetic predisposition (either HLA-DQ2 or HLA-DQ8)
• a well-defined precipitating factor (gluten)
• highly sensitive and specific autoantibodies against the naturally occurring human enzyme, tissue transglutaminase (TG2)
According to the World Gastroenterology Organization, CD may be divided into two types: classical and non-classical. However, silent type CD also exits, which is also known as an asymptomatic CD. In case of silent type, patients do not complain of any symptoms, but still, experience villous atrophy damage to their small intestine. Studies have shown that even though patients thought they had no symptoms, after going on a strict gluten-free diet, they report better health and a reduction in acid reflux, abdominal bloating and distention and flatulence.
Celiac Disease (CD) Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of Celiac Disease (CD), Total Diagnosed Prevalent Population of Celiac Disease (CD), Gender-specific Diagnosed Prevalent Population of Celiac Disease (CD), Type-specific Diagnosed Prevalent Population of Celiac Disease (CD) and Age-specific Distribution of Celiac Disease (CD) in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.
Celiac Disease (CD) Detailed Epidemiology Segmentation
• The total prevalent population of Celiac Disease in the 7 major markets was found to be 6,334,993 in 2017.
• The total 7MM diagnosed prevalent cases of Celiac Disease in 2017 were 1,303,459 out of which the highest diagnosed prevalent cases of this disease were seen in the United States, which was 661,244.
• DelveInsight has found 238,048 and 423,196 cases of males and females in the United States, in 2017.
• It was found that in the United States the number of cases of Classical, Non-classical and Sub-clinical were 178,536, 343,847 and 138,861 respectively, in 2017.
• In the United States the maximum number of cases of Celiac Disease were found in the age group of 19–39 with 241,354 cases in 2017, while the lowest number of cases were found in the age group >80 with 13,224 cases in 2017.
• In the EU5 countries the total prevalent population of Celiac Disease was found to be maximum in Germany with 738,357 cases, followed by the United Kingdom with 650,676 cases in 2017. While, the least number of cases were found in Spain, i.e., 421,326 in 2017.
• In Japan, the prevalence of Celiac Disease was found to be 65,148 in 2017.
Scope of the Report
• The report covers the descriptive overview of Celiac Disease (CD), explaining its causes, signs and symptoms, pathophysiology.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of Celiac Disease (CD).
• The report provides the segmentation of the disease epidemiology for the 7MM by Total Prevalent Population of Celiac Disease (CD), Total Diagnosed Prevalent Population of Celiac Disease (CD), Gender-specific Prevalent Population of Celiac Disease (CD), Type-specific Prevalent Population of Celiac Disease (CD) and Age-specific Prevalent Population of Celiac Disease (CD).
Report Highlights
• Eleven Year Forecast of Celiac Disease (CD)
• 7MM Coverage
• Total Diagnosed Prevalent Population of Celiac Disease (CD)
• Through several secondary sources it is quite evident that the prevalence of Celiac Disease (CD) is higher among females than in males.
• DelveInsight has analyzed type-based data for Celiac Disease (CD). Celiac Disease (CD) can be of three types based on this data, namely, Classical, Non-classical and Sub-clinical Celiac Disease.
• The report also encompasses another major segment, i.e., Age-specific Prevalent Population of Celiac Disease (CD), wherein various age groups have been considered, such as 0–18, 19–39, 49–59, 60–79 and >80. It has been found that the prevalence of Celiac Disease (CD) is maximum in the 19–39 age group.
• Expected Launch of potential therapies, Larazotide Acetate (9 Meters Biopharma), Latiglutenase (ImmunogenX), PRV-015 (Provention Bio) and CNP-101/TAK-101 (Cour Pharmaceuticals/Takeda), may increase the market size in the coming years, assisted by an increase in diagnosed prevalent population of Celiac Disease (CD).
Key Questions Answered
• What is the disease risk, burden and unmet needs of Celiac Disease (CD)?
• What is the historical Celiac Disease (CD) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of Celiac Disease (CD) at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Celiac Disease (CD)?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Celiac Disease (CD) during the forecast period (2020–2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?
Reasons to buy
The Celiac Disease (CD) report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the 7MM Celiac Disease (CD) market.
• Quantify patient share distribution in the 7MM for Celiac Disease (CD).
• The Celiac Disease (CD) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The Celiac Disease (CD) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.
Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook